Interstitial granulomatous dermatitis during talimogen laherparepvec treatment
Authors:
- Marie-Charlotte BrüggenMarie-Charlotte Brüggen
- Simone M. GoldingerSGSimone M. Goldinger
- Reinhard DummerRDReinhard Dummer
- 1 August 2017
- journal article
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 27 (4) , 400-401
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineageJournal of Leukocyte Biology, 2016
- Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus ImmunotherapyClinical Cancer Research, 2016
- The Cytokine GM-CSF Drives the Inflammatory Signature of CCR2+ Monocytes and Licenses AutoimmunityImmunity, 2015
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaJournal of Clinical Oncology, 2015
- Reactive Granulomatous DermatitisDermatologic Clinics, 2015